Navigation Links
First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes

lly significant reduction in plasma glucose levels in diabetic rats treated with dapagliflozin compared to untreated diabetic rats at doses of 0.1 mg/kg and 1.0 mg/kg (-101 mg/dL and -128 mg/dL), respectively (p-value less than 0.0001 at both doses).

About Type 2 Diabetes

Type 2 diabetes is the most common form of diabetes, accounting for approximately 90-95 percent of diabetes cases. Having Type 2 diabetes increases the risk of many serious complications, including heart disease or stroke, high blood pressure, amputation (particularly legs), blindness, nerve damage, and kidney failure. The risk of stroke and the rate of deaths due to heart disease are two to four times higher among people with diabetes, and about 65 percent of deaths among people with diabetes are due to heart disease and stroke.

The A1C test (also known as hemoglobin A1C) is used primarily to monitor the glucose control of diabetics over time. The goal of those with diabetes is to keep their blood glucose levels as close to normal as possible. This helps to minimize the complications caused by chronically elevated glucose levels, such as progressive damage to body organs like the kidneys, eyes, cardiovascular system, and nerves. The A1C test gives a picture of the average amount of glucose in the blood over the last few months. It can help a patient and his doctor know if the measures they are taking to control the patient's diabetes are successful or need to be adjusted.

About Dapagliflozin

Dapagliflozin (previously referred to as BMS-512148) is an investigational drug under development by Bristol-Myers Squibb and AstraZeneca. It is being studied as a once-daily oral antidiabetic. The compound has a novel proposed mechanism of action, selectively inhibiting sodium glucose cotransporter 2 (SGLT2) versus SGLT1, decreasing reabsorption of glucose by the kidneys without affecting SGLT1 in the GI tract. Dapagliflozin has a C-glucoside chemical structure, which prolon
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
9. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
Post Your Comments:
(Date:10/2/2008)... - Dr. Robert Weiss, Director of Maryland Lase... to his practice -, BALTIMORE, Oct. 2 /PRNewswire...gist, is among the first physicians in the U.S. to...ermolysis), the latest,state-of-the-art procedure...ationally renowned dermatologist, who is in privat...
(Date:10/2/2008)... GOTEBORG, Sweden, October 2 /- C...ated dose study in xerostomia ("dry mouth"),patien... be studied in 45,dry mouth patients between the a...select a dose for evaluation in a succeeding Phase...ning the cholinesterase inhibitor,physostigmine. I...
(Date:10/2/2008)... QUEBEC CITY, Oct. 2 / ...a global biopharmaceutical company focused on,endo... has entered the,second stage of patient recruitme...ZS-108, a luteinizing hormone-releasing hormone (L...o enter the second stage of patient,recruitment wa...
(Date:10/2/2008)... OXFORD, England, October 2 /- Ci... focused on the fields of allergy and critical,car... clinical study of its,ToleroMune(R) technology in...itive results achieved in an earlier phase II stud...its of the ToleroMune approach to allergy,desensit...
Breaking Medicine Technology:DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing 2Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology 2Research uncovers the social dynamics of yellow jackets 2253 1Research uncovers the social dynamics of yellow jackets 2253 2Research uncovers the social dynamics of yellow jackets 2253 3Research uncovers the social dynamics of yellow jackets 2253 4Why recovery from flu may increase odds of bacterial infection 12136 1Old London Launches Skinny Jeans Contest 12131 1Old London Launches Skinny Jeans Contest 12131 2Old London Launches Skinny Jeans Contest 12131 3Old London Launches Skinny Jeans Contest 12131 4Into the abyss 3A Deep sixing carbon 2249 1Into the abyss 3A Deep sixing carbon 2249 2
...NJ – June 4, 2007 – Genta,Incorporated...lts,from a Phase 2 clinical trial of its marketed ...plus rituximab (Rituxan®;,Genentech/IDEC) and ...ory non-Hodgkin’s lymphoma (NHL). The data w...n Society of Clinical,Oncology (ASCO) in Chicago, ...
... WIRE)--Jun 4, 2007 - Introgen Therapeutics, Inc.,...ators today,reported updated Phase 2 data demonstr...53, tumor responses and increased,survival followi...quamous cell carcinoma of the head and neck. The d...nnual meeting of the American,Society of Clinical ...
Other Medicine Technology:Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 2Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 3Introgen Reports Updated Phase 2 Advexin Data Correlating Improved,Survival, Tumor Responses and Predictive p53 Biomarker 4
(Date:10/6/2008)...d civil litigation and criminal defense firm resol...warded $3.2 million to plaintiff earlier this year...((Lexis Nexis) October 6, 2008 -- Attorneys in the...tha & Psoras] have successfully resolved a maj...lder who was awarded more than $3 million by a Bal...
(Date:10/5/2008)...g samples distributed to children may be unsafe, a...ealth Alliance and Hasbro Children,s Hospital. The...mple use among children, appears in the October 20...so serve as researchers at Harvard Medical School ...ersity, found that children commonly receive free ...
(Date:10/5/2008)...l a spider as it scurries across the floor. Those...a plane. While nothing physically stops people wi... from the task at hand. , The same could be said...y, according to research presented at the Obesity ...s from the Center for Obesity Research and Educati...
(Date:10/3/2008)...ing is beneficial. But can it help kids lose weigh...erature on obese adolescents, researchers at Duke ...ght type of novel may make a difference. , The D...ho were already in a comprehensive weight loss pro...Rescue (Beacon Street Press). It was carefully cra...
Breaking Medicine News(10 mins):Health News:Miller, Murtha & Psoras Secures Multimillion-Dollar Settlement for Victim of Industrial Accident at Bethlehem Steel 2Health News:Free drug samples carry risks for children 2Health News:Mental barriers hamper obese women's efforts to get exercise 2Health News:Duke researchers show reading can help obese kids lose weight 2
...s from the Harvard School of Public Health now rev...n health risks. They have found that women who car...isk of coronary heart disease. The findings were r... which had collected data on caregiving and corona...
...ming in laboratory studies that one of the substan...hives--may inhibit the development of tooth decay...., found that propolis// considerably reduces denta...r of glucosyltransferase (Gtf) enzymes, enzymes th...
...fferent specialties, recently joined hands to demo...er patients. Dr. Peter Costantino, an otolaryngolo...n fatal tumor in Angela Carrozza’s nasal cavity an...iety of Clinical Oncology, nearly 38,000 cases of ...
...illion people go to the Emergency Room(ER) with ch... Most receive an ECG and other standard tests to d...r serious heart problems. However, ECGs can be com... place. ECGs are also sometimes unable to identify...
Other Medicine News:
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
...ories is a national reference laboratory and a wor...d development. ARUP offers an extensive test menu ...ical and anatomic pathology. Owned by the Universi...e than half of the nation's university teaching ho...
Medicine Products: